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Abstract
DISCLOSURE—The findings and conclusions in this report are those of the authors and do not 
necessarily represent the official position of the Centers for Disease Control and Prevention or the 
Agency for Toxic Substances and Diseases Registry.
OBJECTIVE—Describe the impact of standardizing state-specific summary measures of 
antibiotic resistance that inform regional interventions to reduce transmission of resistant 
pathogens in healthcare settings.
DESIGN—Analysis of public health surveillance data.
METHODS—Central line–associated bloodstream infection (CLABSI) data from intensive care 
units (ICUs) of facilities reporting to the National Healthcare Safety Network in 2011 were 
analyzed. For CLABSI due to methicillin-resistant Staphylococcus aureus (MRSA), extended-
spectrum cephalosporin (ESC)-nonsusceptible Klebsiella species, and carbapenem-nonsusceptible 
Klebsiella species, we computed 3 state-level summary measures of nonsusceptibility: crude 
percent nonsusceptible, model-based adjusted percent nonsusceptible, and crude infection 
incidence rate.
RESULTS—Overall, 1,791 facilities reported CLABSIs from ICU patients. Of 1,618 S. aureus 
CLABSIs with methicillin-susceptibility test results, 791 (48.9%) were due to MRSA. Of 756 
Klebsiella CLABSIs with ESC-susceptibility test results, 209 (27.7%) were due to ESC-
nonsusceptible Klebsiella, and among 661 Klebsiella CLABSI with carbapenem susceptibility test 
results, 70 (10.6%) were due to carbapenem-nonsusceptible Klebsiella. All 3 state-specific 
measures demonstrated variability in magnitude by state. Adjusted measures, with few exceptions, 
were not appreciably different from crude values for any phenotypes. When linking values of 
crude and adjusted percent nonsusceptible by state, a state’s absolute rank shifted slightly for 
MRSA in 5 instances and only once each for ESC-nonsusceptible and carbapenem-nonsusceptible 
Klebsiella species. Infection incidence measures correlated strongly with both percent 
nonsusceptibility measures.
Address correspondence to Minn M. Soe, MD, MPH, MS A-24, CDC, 1600 Clifton Road, NE Atlanta, GA 30333 (msoe@cdc.gov). 
Potential conflicts of interest. All authors report no conflicts of interest relevant to this article.
HHS Public Access
Author manuscript
Infect Control Hosp Epidemiol. Author manuscript; available in PMC 2016 January 01.
Published in final edited form as:













CONCLUSIONS—Crude state-level summary measures, based on existing NHSN CLABSI data, 
may suffice to assess geographic variability in antibiotic resistance. As additional variables related 
to antibiotic resistance become available, risk-adjusted summary measures are preferable.
Healthcare-associated infections (HAIs) caused by antibiotic-resistant bacteria are a serious 
public health threat; they are associated with poorer outcomes and increased cost of care 
compared to HAIs due to antibiotic-susceptible organisms.1–4 The nature and extent of 
antibiotic resistance varies geographically, but the problem is widely prevalent.5–14 
Geographic variability may reflect differences in antibiotic use, infection control, and 
pathogen characteristics of prevalent strains. Complicating the interpretation of regional 
antibiotic resistance assessments is the fact that key metrics and methods of measuring 
antibiotic resistance often vary between regions.5,10–12
In the United States, the Centers for Disease Control and Prevention (CDC) has published 
guidelines for preventing the transmission of antibiotic-resistant pathogens in healthcare 
settings.15 Individual healthcare facilities typically are responsible for implementing 
interventions designed to prevent transmission of HAIs including resistant organisms.16 
However, recent reports have underscored the importance of using regional data to inform 
regional collaborative efforts to reduce HAIs or antibiotic-resistant infections.17–20 CDC has 
published risk-adjusted, state-level summary statistics regarding HAI prevention success.21 
These reports have helped local hospital administrators and state public health authorities 
understand HAI prevention successes and areas in need of improvement.22,23
Similar state-level summary data on antibiotic resistance may help state or regional efforts to 
reduce infections due to antibiotic-resistant bacteria,24 and these data can be useful to aid 
antibiotic stewardship efforts.1 Previous attempts to evaluate regional differences in 
antibiotic resistance among HAIs in the United States have varying results and relied on 
administrative data,10 convenience samples of facilities,9,13,14 or large geographic areas 
aggregating data across many states.12 Surveillance through CDC’s National Healthcare 
Safety Network (NHSN) began in 2006 as a voluntary, hospital-based reporting system to 
monitor HAIs and to inform local and national prevention efforts. When reporting of 
CLABSI from acute care hospital intensive care units (ICUs) was required for participation 
in the Centers for Medicare and Medicaid Services’(CMS) Hospital Inpatient Quality 
Reporting (IQR) program, enrollment expanded to 4,100 healthcare facilities at the 
beginning of 2011.25 However, antibiotic susceptibility data are not reported publically as 
part of this program. As an initial step in developing state/regional summary measures of 
antibiotic resistance, we analyzed central line-associated bloodstream infection (CLABSI) 
data, and we have described an approach to risk-adjusting a state-level metric for direct 
comparison between states and the impact of this risk adjustment. Ultimately, these methods 
can be applied to more representative data to make accurate regional estimates of antibiotic 
resistance.
Soe et al. Page 2















NHSN surveillance processes on CLABSI are described in detail on the CDC website 
(http://www.cdc.gov/nhsn/about.html). Pathogen and antimicrobial susceptibility data 
reported to NHSN are provided by the facility’s designated clinical microbiology laboratory. 
Susceptibility test results must have been reported for a select group of pathogens and 
antimicrobials if testing was performed. Laboratories are expected to use current Clinical 
and Laboratory Standards Institute (CLSI) standards for antimicrobial susceptibility testing. 
Results for each of the selected pathogens were reported to NHSN as the category 
interpretation of “susceptible” (S), “intermediate” (I), “resistant” (R), or “not tested.” We 
limited the analysis to ICUs reporting CLABSIs in 2011 because reporting from these 
locations was nearly complete in 2011 due to the CMS IQR program requirement.25
Selection of Antibiotic-Resistant Infections
For this analysis, 3 distinct antibiotic-resistant phenotypes were identified among ICU 
CLABSI reported to the NHSN: (1) methicillin-resistant Staphylococcus aureus (MRSA), 
defined as S. aureus reported as resistant to oxacillin, methicillin, or cefoxitin; (2) extended-
spectrum cephalosporin (ESC)-nonsusceptible Klebsiella species, defined as K. pneumoniae 
or K. oxytoca reported as I or R to cefotaxime, ceftazidime, ceftriaxone, or cefepime; and (3) 
carbapenem-nonsusceptible Klebsiella species, defined as K. pneumoniae or K. oxytoca 
reported as I or R to imipenem, meropenem, or doripenem.
Statistical Analyses
Statistical analyses were conducted using SAS version 9.3 (SAS Institute, NC) and SAS 
callable SUDAAN version 11.0 (Research Triangle Institute, NC). Frequency distributions 
of selected healthcare facility characteristics were determined for ICU CLABSIs according 
to study isolates or not. To determine factors influencing variability in resistance metrics, 
associations between patient- or facility-level characteristics among ICU CLABSIs due to an 
antibiotic-resistant phenotype were compared to those without resistance using χ2 or 
Fisher’s exact tests as appropriate. A separate analysis was performed for each resistant 
phenotype.
Factors associated with an ICU CLABSI being attributed to an antibiotic-resistant phenotype 
were explored in multivariable regression models including patient-level characteristics 
(age, gender) because these might be plausible indicators of a biological association with 
antibiotic-resistant infections and facility-level percentage of isolates tested for antibiotic 
resistance. Other facility-level characteristics such as facility type, facility bed size, and 
medical school affiliation were evaluated in bivariate analyses but were not considered for 
multivariable modeling. These characteristics may be proxies for factors such as infection 
control practices, for which adjustment may not be appropriate in this setting, and therefore 
we did not include hospital bed size or teaching status into the modeling process. 
Specifically, adjustment would not be appropriate, as doing so would “discount” resistance 
metrics based on poor cross-transmission prevention efforts (if bed size or teaching status 
were proxy measures for such poor efforts) when trying to compare resistance metrics by 
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region, state, or facility. To develop models for each of the 3 phenotypes, multivariable 
logistic regression by the backward elimination method was employed. Because patient age 
was a continuous variable, different parameter categorizations were examined when 
obtaining the best fit model with the smallest AIC and −2 log likelihood value. Statistical 
significance was assessed at the 0.05 level, and all tests were 2-sided.
Calculation of State-Specific Summary Measures of Nonsusceptibility
The infection rate was calculated by dividing the total number of ICU CLABSIs for each 
antibiotic-resistant phenotype in each state by the pooled number of ICU central line days 
for each state. The crude percent nonsusceptible was calculated by dividing the total number 
of ICU CLABSIs for each antibiotic-resistant phenotype in each state by the total number of 
ICU CLABSI isolates of S. aureus or Klebsiella species tested for susceptibility to at least 1 
of the antibiotics within the antibiotic-resistant phenotype definition.26 For MRSA, the 
percent nonsusceptible is equivalent to the percent resistant because, by definition, there are 
no breakpoints for S. aureus for testing intermediate (I) to oxacillin or cefoxitin.
A third state summary metric, the adjusted percent non-susceptible, was calculated for direct 
comparison between states. Adjusted percent nonsusceptible for each phenotype was 
computed for states reporting antibiotic susceptibility test results from a minimum of 20 ICU 
CLABSI isolates of S. aureus or Klebsiella species to impose statistical precision. Among 
these states, state-specific point estimates of adjusted percent nonsusceptible were obtained 
as functions of predicted marginals by multivariable logistic regression using SAS-callable 
SUDAAN. Marginal prediction takes a model-based approach to computing standardized 
estimates and allows comparisons of predicted outcomes (percent nonsusceptible) between 
groups after controlling for differences in covariate distributions.27 Therefore, standardized 
results from fitted logistic regression models can be compared like percentages (percent 
non-susceptible) across these states. To compute 95% confidence intervals of the metrics, 
variance estimates of unadjusted and adjusted percent nonsusceptible were obtained using 




During 2011, 22,561 CLABSIs were reported from 2,212 facilities (58.0% of the total 
facilities participating in NHSN CLABSI reporting); 1,145 facilities (51.8%) reported at 
least 1 S. aureus CLABSI, and 732 (33.1%) reported at least 1 Klebsiella CLABSI (Table 
1).
Crude Distributions of Nonsusceptible Isolates by Facility and Patient Characteristics
Of 1,750 S. aureus CLABSIs reported from ICUs, methicillin susceptibility test results were 
available in 1,618 isolates, among which 791 (48.9%) were due to MRSA. Of 889 Klebsiella 
CLABSIs reported from ICUs, ESC susceptibility test results were available in 756 isolates, 
among which 209 (27.7%) were due to ESC-nonsusceptible Klebsiella, and carbapenem 
susceptibility test results were available in 661 isolates, of which 70 (10.6%) were due to 
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carbapenem-nonsusceptible Klebsiella. For all phenotypes, there was no significant 
difference in the percent nonsusceptible among males and females, while increasing age was 
significantly associated with decreasing susceptibility (Table 2). There was a significant 
difference in the percent nonsusceptible among the patient locations for all phenotypes, with 
adult locations having higher levels of resistance than neonatal and pediatric locations. 
However, differences between adult ICU and non-ICU locations, and between pediatric ICU 
and non-ICU locations, were in most cases small and not statistically significant (data not 
shown). Isolates from smaller hospitals and those without medical school affiliations were 
significantly more likely to be nonsusceptible than isolates from larger hospitals or hospitals 
with medical school affiliations (Table 2). Approximately 37% of Staphylococcus aureus 
isolates and 27% of Klebsiella species in medical school–affiliated hospitals came from 
infants. Similar proportions of study isolates in large hospitals (>200 beds) were obtained 
regarding infants.
Adjusted State-Specific Summary Measure of Non-susceptibility
Although the proportion of isolates tested for the relevant antibiotic susceptibility varied 
between facilities (and states), this variation was not significantly associated with the 
percent nonsusceptible and was dropped from the model-building process. The final 
regression models included age divided into 3 or 4 categories, depending on the resistant 
phenotype (Table 3). Controlling for age in these models, the adjusted percent non-
susceptible of each resistant phenotype was calculated. The crude infection rate, crude 
percent nonsusceptible, and adjusted percent nonsusceptible values are plotted in Figure 1 
(and the Appendix).
For MRSA, 24 states had sufficient data to calculate an adjusted measure. The adjusted 
percent nonsusceptible values differed only slightly from crude percent nonsusceptible 
values (Figure 1A), in all cases by fewer than 5%, and usually within 1%–2%. The 
variability of the state-specific crude percent nonsusceptible (range: 26%–64%) and adjusted 
percent nonsusceptible (range: 27%–66%) was large (Figure 2), with only a slight narrowing 
of the interquartile range in the adjusted measure compared to the crude measure (~19%–
16%). In 5 instances (states 2, 13, 18, 27, and 35), a state’s rank shifted relative to the 
position of other states based on the respective measure (Figure 3A).
For ESC-nonsusceptible Klebsiella spp., 11 states had sufficient data to calculate an adjusted 
measure. Compared to crude percent nonsusceptible measures, the adjusted percent 
nonsusceptible values differed appreciably in only 2 states: state 15 with a lower adjusted 
value by 7%, and state 3 with a lower adjusted value by 17% (Figure 1B); otherwise, 
differences were minor (0–4%). The variability of the state-specific measures of crude 
percent nonsusceptible (range: 20%–80%) and adjusted percent nonsusceptible (range: 
21%–63%) was large (Figure 2), but the interquartile range in the adjusted measure was 
narrower (17%) compared with that in the crude measure (25%). In only 1 instance did the 
state’s value shift ranking relative to the position of other states based on the respective 
measure (ie, only 1 line crossed other lines in state 36) (Figure 3B).
For carbapenem-nonsusceptible Klebsiella spp., 9 states had sufficient data to calculate an 
adjusted measure. The adjusted percent nonsusceptible values differed appreciably from the 
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crude percent nonsusceptible only in state 3, with a lower adjusted value by 10%; this state 
happened to be the same state with a large difference between adjusted and crude measures 
for ESC-nonsusceptible Klebsiella spp. (Figure 1C). Differences in all other states were 
minor (1%–4%). The variability of the state-specific measures of crude percent 
nonsusceptible (range: 2%–35%) and adjusted percent nonsusceptible (range: 3%–25.3%) 
was again large (Figure 2). There was essentially no difference in the size of the interquartile 
range between the adjusted measure and the crude measure (Figure 2). In only 1 instance 
(state 3) did the state’s value shift in rank (Figure 3C).
DISCUSSION
Using susceptibility data for S. aureus and Klebsiella CLABSIs reported from ICUs to the 
NHSN in 2011, we have demonstrated that the extent of antibiotic resistance varies 
considerably between different states. Among the 3 state-level summary measures of 
nonsusceptibility that we explored, the most state-to-state variability was seen for the crude 
percent of isolates testing nonsusceptible. However, the age-adjusted state-summary 
resistance measure (ie, adjusted percent nonsusceptible), with few exceptions, did not 
appreciably change the state-specific values either in magnitude or relative to other states 
compared to the crude measure.
State-level summary antibiotic resistance measures have public health implications. 
Summary measures have the potential to inform empiric treatment recommendations where 
local representative data are not available. Second, utilizing a state-specific summary 
measure should allow providers and public health agencies at the state level to gain 
situational awareness around the magnitude of the resistance problem in their jurisdictions, 
more so than if they relied on data from a few selected healthcare facilities. This is 
especially true regarding resistant phenotypes of an urgent threat nature, such as 
carbapenem-resistant Enterobacteriaceae (CRE). The variability in resistance measures 
reflected in these data supports other studies’ findings of regional variability in resistance 
related to HAIs. It also supports the notion that 1 single approach to reducing infections with 
antibiotic-resistant bacteria may not be appropriate for all locales.10,12,29
Unique to this analysis is our adjustment of a summary measure of antibiotic resistance 
through a modeling process, which allows for valid comparisons between state-specific 
measures. The direct standardization method that summarizes the measure across adjusting 
categories is commonly used for comparison between groups.30 However, in states with 
small values for tested isolates, many categories have small cell sizes or empty cells, leading 
to unstable category-specific rates to calculate adjusted summary measures. In addition, 
some of the adjusting variables may be continuous in nature, and it may be difficult to 
optimize the categorization of these variables, making direct standardization less feasible. 
The model-based approach can circumvent these inherent limitations in the direct 
standardization method. Unfortunately, even with the model-based method, the lack of 
appreciable changes in the adjusted measure compared to the crude measure likely reflects 
an absence of adequate factors to incorporate into the modeling process (residual 
confounding). Such factors, those that are associated with resistance at the patient level but 
are not confounded by facility-specific infection control activity, are limited in our current 
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data set (eg, age, gender). Additional opportunities for improved adjustment of state 
summary resistance measures include incorporation of patient-level or ward-level severity 
measures or more likely hospital-wide severity of illness measures such as a case mix 
index.31 Ideally, measures used to compare one state to another should be as risk adjusted as 
possible. For now, given the limited availability of adjustment factors that systematically 
influence the values, crude summary measures of resistance appear to be a reasonable 
approach to evaluating geographic differences in summary resistance patterns.
There were notable differences in the impact of adjustment on specific resistant phenotypes. 
For MRSA there was minor impact: although 5 states shifted their relative ranking to one 
another, the change in the value of the resistance measure was small. In contrast, for the 
most uncommon resistant phenotype, carbapenem-nonsusceptible Klebsiella spp., the state 
with the highest crude value had a substantial decrease (10%) in the percent nonsusceptible 
after age adjustment because, unlike other states, all ICU patients with Klebsiella CLABSIs 
in that state were 21 years and older, apparently inflating the crude percent nonsusceptible. 
Despite this, the overall variability in the percent nonsusceptible did not change with 
adjustment; the range and interquartile range essentially stayed the same. This finding 
suggests that the variability of antimicrobial resistance among the states is likely related to 
factors (other than age) such as cross-transmission between patients or facilities.
A notable observation that CLABSIs reported from large, academic hospitals have less-
resistant pathogens than those from smaller non-academic hospitals could be partly 
explained by the presence of large proportions of infants represented in the patient 
population with CLABSIs in these large, academic hospitals, and these infants least often 
had resistant pathogens.
Overall, these data indicate that crude summary measures of resistance may suffice at 
present for assessing geographic variability. However, the generalizability of this finding is 
constrained by several study limitations. The isolates obtained from CLABSI do not 
represent hospital patients in general. Although we adjusted for state differences in age 
distributions, additional explanation for regional variability in antibiotic resistance could 
range from differences in laboratory testing standards and reporting bias to differences in 
patient mix. Data used in the analysis are for a small fraction of HAIs; CLABSIs account for 
<10% of HAIs occurring in acute care hospitals.32 Therefore, the magnitudes of the 
proportions presented in this paper do not reflect the magnitude of resistance problem 
accurately; however, we believe they do reflect the impact of adjusting these summary 
measures accurately. It is possible that the variability of, and impact of adjustment on, 
resistance measures may differ for other HAI types, and this topic requires further analysis.
Additional limitations include the relatively small number of states represented in some 
comparisons. Although eliminating summary values comprised of fewer than 20 isolates 
helped to exclude outliers, it reduced the number of states included in each analysis. 
Similarly, although all facilities within a state reporting to NHSN could have contributed 
data to the state summary value, only those that did report a CLABSI are represented in the 
percent nonsusceptible measure. However, we did also construct crude resistance infection 
incidence measures that included exposure data (ie, cumulative central line days) from all 
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facilities reporting CLABSI data to NHSN and is more representative of facilities within the 
state. This measure has an added advantage of better reflecting infection burden compared to 
the percent nonsusceptible.33
Reducing the transmission of antibiotic-resistant bacteria in healthcare settings remains a 
high priority for patients, healthcare providers, and public health agencies. Although the 
relative value of the different tools in place for hospitals and local health departments to 
reduce these infections is still uncertain, state-specific summary measures (which ideally 
include all infection types) should be able to provide health authorities and healthcare 
providers within a region or state situational awareness of the magnitude of the resistance 
problem in their area. The improvement of such measures by identifying and applying 
factors such as laboratory practices and patient mix into a risk adjustment strategy and by 
incorporating test results from more clinical cultures is needed. However, producing state 
summary resistance measures and assessing their utility using existing national data will be a 
critical first step toward reducing the emergence and spread of antibiotic resistance in US 
hospitals.
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State-specific rate and percentage of isolates with resistant phenotypes, reported as central 
line-associated bloodstream infections (CLEBSIs) from intensive care units, National 
Healthcare Safety Network, 2011. Triangle represents point estimate of rate per 1,000 device 
days, open bar represents crude proportion and grey bar represents adjusted proportion. 
Graph 1A represents methicillin-resistant Staphylococcus aureus (MRSA). Graph 1B 
represents extended-spectrum cephalosporin-nonsusceptible (ESC-NS) Klebsiella spp. 
Graph 1C represents carbapenem-nonsusceptible (C-NS) Klebsiella spp.
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Distributions of state-specific percentage of pathogenic central line-associated bloodstream 
infection (CLEBSI) isolates nonsusceptible to selected antibiotics in intensive care units, 
unadjusted (crude) vs. adjusted (model-based) values, National Healthcare Safety Network, 
2011. MRSA, methicillin resistant S. aureus; ESC-NS, extended-spectrum cephalosporin-
nonsusceptible Klebsiella spp.; C-NS, carbapenem-nonsusceptible Klebsiella spp. 
Horizontal lines represent maximum, minimum, 75th, 50th, and 25th percentile values. 
Diamond represents the mean value.
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Linked values of unadjusted (crude) and adjusted (model-based) state-specific percentage of 
isolates with selected resistance phenotype among central line-associated bloodstream 
infections (CLEBSIs) from intensive care units, by state, National Healthcare Safety 
Network, 2011. Graph 3A represents methicillin-resistant Staphylococcus aureus (MRSA). 
Graph 3B represents extended-spectrum cephalosporin-nonsusceptible (ESC-NS) Klebsiella 
spp. Graph 3C represents carbapenem-nonsusceptible (C-NS) Klebsiella spp.
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TABLE 3
Multivariable Analysis of Factors associated with Resistant Phenotypes among Isolates associated with 
Central Line-Associated Bloodstream Infections from Intensive Care Units, National Healthcare Safety 
Network, 2011
Phenotype, parameter a Age, yrs % nonsusceptible Parameter estimate Adjusted OR (95% CI)
Methicillin resistant Staphylococcus aureus (N = 1,618)
 Age group b 85 + 69.0 1.5 4.7 (2.6–8.4)
30–84 56.5 1.0 2.7 (2.2–3.4)
21–29 63.2 1.3 3.6 (2.0–6.4)
1–20 38.7 0.3 1.3 (0.8–2.3)
<1 32.2 Reference
Extended-spectrum cephalosporin- nonsusceptible Klebsiella spp. (N = 756)
 Age group b 65 + 38.2 4.0 56.9 (13.8–234.7)
1–64 34.9 3.9 49.3 (12.0–202.2)
<1 1.1 Reference
Carbapenem-nonsusceptible Klebsiella spp. (N = 661)
 Age group b 65 + 18.0 2.4 11.2 (3.9–32.0)
21–65 11.6 1.9 6.7 (2.3–19.3)
<21 1.9 Reference
NOTE. Methicillin resistance was defined as resistant to oxacillin, cefoxitin, or methicillin. Extended-spectrum cephalosporin-nonsusceptible was 
defined as K. pneumoniae or K. oxytoca testing intermediate (I) or resistant (R) to cefotaxime, ceftazidime, ceftriaxone or cefepime.
Carbapenem-nonsusceptible was defined as K. pneumoniae or K. oxytoca reported as I or R to imipenem, meropenem, or doripenem. OR, odds 
ratio; CI, confidence interval; N, number of isolates.
a
Eligible parameters gender and facility-level percentage of isolates tested for antibiotic resistance, were not statistically significant and therefore 
dropped in the final models of all 3 phenotypes.
b
This final model with specified age groups is the best fit model with the smallest AIC and −2 log likelihood value after different age parameter 
categorizations were examined including age as a continuous variable.
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